HALBERD CORP - HALB STOCK NEWS

Halberd Corporation (OTC PINK:HALB) has achieved a significant breakthrough in treating neurodegenerative diseases by successfully eliminating glutamate from cerebral spinal fluid. This advancement allows control over ten disease-associated antigens, opening new treatment possibilities for conditions like PTSD, Alzheimer's, and more. The company intends to validate efficacy through animal testing and is pursuing FDA certification. Additionally, Halberd is collaborating with universities and research organizations to advance its initiatives. This solution could benefit millions suffering from neurodegenerative disorders.

Halberd Corporation (OTC PINK:HALB) has successfully eliminated 100% of Tau protein from cerebral spinal fluid in less than 20 minutes using its patented laser exposure process. This marks the ninth of ten neurodegenerative disease target antigens the company has addressed. Dr. Mitchell S. Felder highlighted that Halberd's approach effectively removes disease precursors without introducing foreign substances. CEO William A. Hartman expressed confidence in eliminating the remaining target antigen, glutamate, and aims to seek partnerships for effective treatments in various neurodegenerative diseases.

Halberd Corporation (OTC PINK:HALB) has achieved a breakthrough in the treatment of Alzheimer's Disease by selectively eliminating Tau proteins from a mixture without affecting non-target cytokines. This was accomplished using Halberd's proprietary extracorporeal laser exposure process in synthetic cerebral spinal fluid, a substitute for human CSF. Dr. Mitchell S. Felder described this as a landmark achievement that opens new avenues for treating various diseases with precision. Halberd holds exclusive rights to three issued patents and continues to file related patent applications to secure its innovations.

Halberd Corporation (OTC PINK: HALB) provides an overview of its achievements and goals for 2022. The company focuses on biomedical R&D, targeting neurodegenerative diseases, with a proprietary treatment methodology. Key milestones include successful eradication of top antigens linked to diseases, the addition of patents, and plans for joint ventures and government grants. Forward goals encompass completing independent audits, filing a FORM-10, and expanding outreach and product lines. Halberd aims to enhance its technical capabilities and brand recognition to assure success for shareholders.

Halberd, Inc. (HALB) has achieved significant progress in its latest laboratory tests, successfully eliminating Beta Amyloid and Interleukin-4 from synthetic cerebrospinal fluid (CSF). This accomplishment aligns with HALB's objective to manage key antigens associated with neurodegenerative diseases such as Alzheimer's, PTSD, and ALS. The company has completed eradication tests for multiple target antigens and boasts three issued patents related to this technology. CEO William A. Hartman emphasized the uniqueness of HALB's approach compared to competitors, which reportedly eliminate only a fraction of Beta Amyloid.

Halberd Corporation (OTC PINK:HALB) is now registered with the Federal Government's System for Award Management, enabling it to bid on Federal contracts in biotechnology research and health supplements. This opens opportunities to serve military members and government agencies addressing neurodegenerative diseases like PTSD, Alzheimer's, and more. The company claims proof-of-concept for removing disease-related antigens from cerebral spinal fluid and plans to advance to in-vivo studies. Halberd has secured three patents and filed numerous applications to boost its market presence.

Halberd Corporation (OTC Pink: HALB) has successfully eliminated Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary tests. IL-2, a pro-inflammatory cytokine, is linked to neurodegeneration and neuroprotection in conditions like Alzheimer's Disease. Dr. Mitchell S. Felder emphasized this ability could halt Alzheimer's progression when combined with controls on other inflammatory cytokines. CEO William A. Hartman stated that this technology could revolutionize treatment for various neurodegenerative diseases and may lead to breakthroughs for related diseases like cancer.

Halberd Corporation (OTC PINK:HALB) announced a breakthrough in its ongoing research, achieving 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid. This pro-inflammatory cytokine has been linked with Alzheimer's Disease, affecting over 6 million people in the U.S. and 40 million worldwide. CEO William A. Hartman mentions this technology aims to eliminate antigens related to neurodegenerative diseases, positioning Halberd as a unique player in this field. The company's future plans include promoting this technology to target conditions like Traumatic Brain Injury and PTSD.

Halberd Corporation (OTC PINK:HALB) announced a breakthrough achievement in neuroscience by successfully eradicating Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) during preliminary testing. This advancement is critical, as IL-1 is linked to various severe diseases including Alzheimer's and Multiple Sclerosis. The company's patented technology has previously eliminated other inflammatory cytokines, enhancing prospects for treating neurodegenerative conditions. Halberd aims to revolutionize treatments for diseases such as Alzheimer’s and Parkinson’s through ongoing research and patent protections.